((自动化翻译由路透提供，请见免责声明 ))
9月16日 - ** 癌症药物开发商Iteos Therapeutics 股价盘前上涨14.7%，报19.16美元
** 该公司称，其肺癌药物belrestotug与葛兰素史克 的药物dostarlimab联合使用后，63.3%-76.7%的患者肿瘤缩小或消失，而只使用葛兰素史克药物的患者肿瘤缩小或消失的比例为37.5%。
** 葛兰素史克公司的抗癌药物多司他利单抗以 Jemperli 品牌销售
** 在一种被称为非小细胞肺癌的晚期肺癌患者中测试了这种组合药物
** 截至上一交易日收盘，股价累计上涨 52.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.